Owlstone Medical secures investment from Cystic Fibrosis Foundation

Owlstone Medical (“Owlstone”), the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced that the Cystic Fibrosis Foundation has made an up to USD $2.3 million equity investment (circa £1.7 million) in Owlstone to develop a breath test for Pseudomonas aeruginosa (PA) detection in patients with cystic fibrosis (CF).

Leave a Reply